FDA 483 - DermAvance Pharmaceuticals, Inc. - July 17, 2018

DermAvance Pharmaceuticals, Inc., a Commercial Sponsor-Monitor, was cited for a compliance issue during an FDA inspection. The firm failed to submit required annual progress reports for a significant risk device study. Specifically, the annual progress report for 2017 was not submitted to the FDA.